39802-78-3

Basic information

• Product Name: 4-(2-CHLOROPHENYL)BENZALDEHYDE
• Synonyms: AKOS BAR-0181;4-(2-CHLOROPHENYL)BENZALDEHYDE;2'-CHLORO-[1,1'-BIPHENYL]-4-CARBOXALDEHYDE;2'-CHLORO[1,1'-BIPHENYL]-4-CARBALDEHYDE;2'-CHLORO-BIPHENYL-4-CARBALDEHYDE;4-(2-Chlorophenyl)benzaldehyde, 2-Chloro-4'-formylbiphenyl;2'-Chloro-biphenyl-4-carboxaldehyde
• CAS NO: 39802-78-3
• Molecular Formula: C₁₃H₉ClO
• Molecular Weight: 216.66
• Product Categories: pharmacetical
• Mol File: 39802-78-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 338.9 °C at 760 mmHg
• Flash Point: 178.3 °C
• Appearance: /
• Density: 1.214g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(2-CHLOROPHENYL)BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-CHLOROPHENYL)BENZALDEHYDE(39802-78-3)
• EPA Substance Registry System: 4-(2-CHLOROPHENYL)BENZALDEHYDE(39802-78-3)

Safety Data

• Hazardous Substances Data: 39802-78-3(Hazardous Substances Data)

Usage

Uses

2''-Chloro[1,1''-biphenyl]-4-carbaldehyde is a reagent used in the synthesis and screening of cyanopyrans with antimicrobial activities.

Upstream product

• 109524-03-0 2'-chlorobiphenyl-4-ylmethanol 
• 3808-93-3 2'-chloro[1,1'-biphenyl]-4-carboxylic acid 
• 89900-96-9 2'-chlorobiphenyl-4-carboxylic acid methyl ester 
• 694-80-4 2-bromo-1-chlorobenzene 
• 87199-17-5 4-formylphenylboronic acid, 
• 3900-89-8 2-Chlorobenzeneboronic acid 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 726136-65-8 2'-chloro-N-methyl-[1,1'-biphenyl]-4-methanamine 
• 516481-29-1 2-[4-(2-Chloro-phenyl)-phenyl]-1H-benzoimidazole-5-carboxylic Acid Amide 
• 39802-79-4 4-(2'-chlorophenyl)cinnamic acid 
• 57592-01-5 (E)-4-(2'-chloro-4-biphenylyl)-3-buten-2-one 
• 1144106-48-8 C₂₁H₁₈ClNO 

Relevant articles and documents

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease

Monoamine oxidase-B (MAO-B) is a well-established therapeutic target for Parkinson’s disease (PD); however, previous clinical studies on currently available irreversible MAO-B inhibitors have yielded disappointing neuroprotective effects. Here, we tested the therapeutic potential of KDS2010, a recently synthesized potent, selective, and reversible MAO-B inhibitor in multiple animal models of PD. We designed and synthesized a series of α-aminoamide derivatives and found that derivative KDS2010 exhibited the highest potency, specificity, reversibility, and bioavailability (> 100%). In addition, KDS2010 demonstrated significant neuroprotective and anti-neuroinflammatory efficacy against nigrostriatal pathway destruction in the mouse MPTP model of parkinsonism. Treatment with KDS2010 also alleviated parkinsonian motor dysfunction in 6-hydroxydopamine-induced and A53T mutant α-synuclein overexpression rat models of PD. Moreover, KDS2010 showed virtually no toxicity or side effects in non-human primates. KDS2010 could be a next-generation therapeutic candidate for PD.

PIPERIDINES USEFUL FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

The invention relates to compounds which are substituted chiral or achiral derivatives of 3- or 4- aminopiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula I and especially their use as inhibitors of β-secretases.

Comparison of the Properties of Liquid Crystals Derived from Certain Lateral Halogeno-substituted Azomethines

Twenty-eight 4-n-alkoxy-N-(2- and 2'-halogenobiphenyl-4-ylmethylene)anilines comprising 4,8,8,4, and 4 members derived , respectively, from 2-fluoro-, 2'-fluoro-, 2'-chloro-, 2'-bromo-, and 2'-iodo-biphenyl-4-carbaldehyde, together with six 4-p-n-alkoxy-2'-fluorobenzylideneaminobiphenyls have been prepared.The liquid crystal behaviour of these compounds has been compared with analogous azomethines with reversed CH=N linkage, previously reported.